Last reviewed · How we verify
Videx EC
Videx EC is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.
Videx EC is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating. Used for HIV-1 infection (in combination antiretroviral therapy).
At a glance
| Generic name | Videx EC |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Didanosine (the active ingredient in Videx EC) is phosphorylated intracellularly to didanosine triphosphate, which inhibits HIV reverse transcriptase and terminates viral DNA chain elongation. The extended-release formulation (EC) provides sustained drug levels with once-daily dosing, improving adherence compared to immediate-release formulations.
Approved indications
- HIV-1 infection (in combination antiretroviral therapy)
Common side effects
- Pancreatitis
- Peripheral neuropathy
- Diarrhea
- Nausea
- Headache
- Lactic acidosis
Key clinical trials
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs (PHASE1, PHASE2)
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth (PHASE3)
- Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers (PHASE1)
- One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine (PHASE2)
- A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine (NA)
- Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Videx EC CI brief — competitive landscape report
- Videx EC updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI